Skip to main content

IRBs in Developing Countries

BayBiotech.NET
Conducting clinical trials in developing countries usually are faced with several local challenges and one of them is lack of local Institutional Review Board (IRBs) to review the informed consents and study protocols as well as monitor the study. Mostly, if a clinical trial is initiated outside US, the IRB within United States guides the trial. Mostly, in developing countries maintaining an efficient IRB is considered an extra financial burden on the system. Thus, a US sponsor in a developing country may face the challenges as the views on the judgment about risks and benefits of a trial may differ between the countries. In addition, developing informed consents become a main barrier due to a low literacy rate.
Thus, the best solution to this could be that two IRB committees oversee the work, one based in United States as well as one in the developing country. The US sponsor must ensure the existence of such an IRB in the country of interest. The IRB in the country of interest may have a US member who must have either loved or worked in the country and understand the local issues around specific disease or population. This will help in developing appropriate level of informed consents as well as study protocols.
Sufficient efforts must be in place to improve the competency of IRB committees in developing countries as well as the advice of the IRB committees in developing countries should be respected. Follow the link http://johnmm.bol.ucla.edu/irbReview.htm# to read more on this.

Comments

Post a Comment

Popular posts from this blog

Amendments for High Risk Device Type Regulatory Pathway

BayBiotech.NET Government Accounting Office (“GAO”) has issued a long-awaited report evaluating the use of the 510(k) process by the Food and Drug Administration (“FDA” or the “Agency”) in the January of 2009. Report mainly focused on Preamendment class III devices. Although most high-risk class III medical devices are subject to the demanding premarket approval (“PMA”) process, preamendment class III devices may be cleared through the 510(k) pathway until FDA issues regulations requiring a PMA. Under the Safe Medical Devices Act of 1990, FDA was required either to reclassify preamendment class III devices into class I or II, or (2) issue regulations requiring PMA approval for the devices, GAO noted that 20 preamendment class III device types have not yet been addressed by the Agency. GAO has urged FDA to take required steps to address the remaining class III devices that continue to be eligible for 510(k) review. As a result of the report, FDA has committed to address al...
Post a Comment
Read more

Harmonization by Doing (HBD): Japan & U.S. Collaboration

BayBiotech.NET HBD is an international cooperative effort by Japan and US for regulatory convergence for Medical Devices. The efforts are focused on to develop global clinical trials and address regulatory barriers for timely device approvals. To address the needs for additional evaluation, the HBD initiative is a pilot project launched jointly by FDA and MHLW-PMDA for the premarket review of device cardiovascular technology. Instead of taking a theoretical approach to harmonization, HBD is focused on Proof of concept by utilizing parallel development, application submissions and review of actual medical device projects. HBD Study intends to collect and analyze regulatory submission data from multiple applications in the U.S. and Japan. The purpose of the study is to further understand differences that may exist with format and content, to define best practices and to improve globally harmonized processes. To read more about the HBD program, follow the link: http://www.fda.gov/M...
Post a Comment
Read more

What to include in Traditional 510(k) Filing for Medical Devices

BayBiotech.NET A 510k is a premarket submission made to FDA to demonstrate that a medical device to be marketed is at least as safe and effective, that is, substantially equivalent, to a legally marketed device. A Traditional 510(k) submission must include the required elements as per 21 CFR 807.87 (Information required in a premarket notification submission):  the name of device, (the trade or proprietary name), if any, and the common or usual name or classification name of the device.  description of the device, include device specifications and reference applicable guidance documents, special controls, or standards; photographs or engineering drawings should be supplied, if applicable.  comparison with a predicate device(s), indicating similarities and/or differences accompanied by data, as appropriate; this information may include an identification of materials, design considerations, energy expected to be used or delivered by the device, and a description of the operatio...
Post a Comment
Read more